Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOSTEM
2024-516421-30-00Phase 2Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous cord blood-derived mononuclear cells in hypoxic-ischemic encephalopathy (HIE), sponsored by Assistance Publique–Hôpitaux de Marseille. Primary endpoints: Occurrence of clinical or paraclinical adverse events attributable to the injected cell preparation and Feasibility of the study. Planned start Sep 2024; status: authorised.
02
Drugs
autologous cord blood-derived mononuclear cells
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2024-516421-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516421-30-00.